Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 8/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8074670 | 0.88 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL27792588 | 0.88 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL27813851 | 0.88 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL224930 | 0.85 | EPHX1 (0.51) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL11921121 | 0.85 | EPHX1 (0.51) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL224929 | 0.85 | EPHX1 (0.51) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL28984106 | 0.82 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL28984107 | 0.82 | EPHX1 (0.46) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL31721375 | 0.81 | DRD2 (0.41) | EPHX1DRD2BTKKDM1AMAOB | |
| SCHEMBL20865563 | 0.81 | BTK (0.51) | EPHX1DRD2BTKKDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509591-B1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | HIGHLIGHTLL PHARMACEUTICAL HAINAN CO LTD (CN) | 2021-11-17 | — | — | EP | disclosed |
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | TLL Pharmaceutical, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| WO-2018067422-A1 | NOVEL JAK1 SELECTIVE INHIBITORS AND USES THEREOF | LIANG CONGXIN (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738060-B2 | JAK1 selective inhibitors and uses thereof | JAK1, JAK3, JAK2 | EPHX1 3526/4885DRD2 3008/4885BTK 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.